References
- MyasoedovaECynthiaSCHilalMTerryMTSherineEGIs the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007Arthritis Rheum2010621576158220191579
- SanchezCMathy-HartertMDebergMAFicheuxHReginsterJYHenrotinYEEffects of rhein on human articular chondrocytes in alginate beadsBiochem Pharmacol20036537738812527330
- Alvarez-SoriaMAHerrero-BeaumontGSanchez-PernauteOBellidoMLargoRDCN has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast – comparison to its effects on osteoarthritic chondrocytesRheumatology20084762763318375401
- MaskiNKumaranAGirhepunjeKGhodePRandiveSPalRStudies on the preparation, characterization and solubility of β-cyclodextrin-DCN inclusion complexesInt J Pharm Pharm Sci20091121135
- NicolasPTodMPadoinCPetitjeanOClinical pharmacokinetics of diacereinClin Pharmacokinet1998353473599839088
- DougadosMNguyenMBerdahLMaziéresBVignonELequesneMECHODIAH Investigators Study GroupEvaluation of the structure-modifying effects of DCN in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hipArthritis Rheum2001442539254711710710
- BrahmachariBChatterjeeSGhoshAEfficacy and safety of DCN in early knee osteoarthritis: a randomized placebo-controlled trialClin Rheumatol200981193119819597913
- European Medicine AgencyPRAC recommends suspension of diacerein-containing medicinesLondon, UKEuropean Medicine Agency Online Resources, Inc2013 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001947.jsp&mid=WC0b01ac058004d5c1Accessed November 10, 2013
- Ramos-ZavalaMGGonzález-OrtizMMartínez-AbundisERobles-CervantesJAGonzález-LópezRSantiago-HernándezNJEffect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trialDiabetes Care2011341591159421610123
- MehnertWMäderKSolid lipid nanoparticles. Production, characterization and applicationsAdv Drug Deliv Rev20014716519611311991
- KhalilRMEl-BaryAAKassemMAGhorabMMAhmedMBSolid lipid nanoparticles for topical delivery of meloxicam: development and in vitro characterizationPresented at the Annual International Interdisciplinary ConferenceApril 24–26, 2013Azores Islands, Portugal
- MühlenASchwarzCMehnertWSolid lipid nanoparticles (SLN) for controlled drug delivery – drug release and release mechanismEur J Pharm Biopharm1998451491559704911
- JohDYKaoGDMurtySTheranostic gold nanoparticles modified for durable systemic circulation effectively and safely enhance the radiation therapy of human sarcoma cells and tumorsTransl Oncol2013672273124466375
- HussainIHussainSZHabib-ur-RehmanIn situ growth of gold nanoparticles on latent fingerprints – from forensic applications to inkjet printed nanoparticle patternsNanoscale201022575257820959933
- JenningVMäderKGohlaSHSolid lipid nanoparticles (SLN™) based on binary mixtures of liquid and solid lipids: a 1H-NMR studyInt J Pharm2005205152111000538
- Research Unit of General Practice, CopenhagenImplantation of gold beads to relieve discomfort from knee osteoarthritisBethesda, MD, USANational Institutes of Health2007 Available from: http://clinicaltrials.gov/show/NCT00487370Accessed November 23, 2014
- RothenfluhDABermudezHO’NeilCPHubbellJABiofunctional polymer nanoparticles for intraarticular targeting and retention in cartilageNat Mater2008724825418246072
- YeoYBaekNParkKMicroencapsulation methods for delivery of protein drugsBiotechnol Bioprocess Eng20016213230
- MaoSRWangYZJiHYBiDZPreparation of solid lipid nanoparticles by microemulsion techniqueYao Xue Xue Bao200338624626 Chinese14628457
- KumarPPGayatriPSunilRJaganmohanSRaoYMAtorvastatin loaded solid lipid nanoparticles: formulation, optimization, and in vitro characterizationIOSR J Pharm201322332
- ChavdaHPatelJChavadaGDaveSPatelAPatelCSelf- nanoemulsifying powder of isotretinoin: preparation and characterizationJ Powder Technol20132013108569
- ClogstonJDPatriAKZeta potential measurementMethods Mol Biol2011697637021116954
- JainAKumarSSYuvrajSSanjaySDevelopment of lipid nanoparticles of DCN, an antiosteoarthritic drug for enhancement in bioavailability and reduction in its side effectsJ Biomed Nanotechnol2013989190023802421
- AkbariBTavandashtiMPZandrahimiMParticle size characterization of nanoparticles – a practical approachIran J Mater Sci Eng201184856
- MullerRHMaderKGohlaSSolid lipid nanoparticle (SLN) for controlled drug delivery – a review of the state of the artEur J Pharm Biopharm20005016117710840199
- LobovkinaTJacobsonGBGonzalezEGIn vivo sustained release of siRNA from solid lipid nanoparticlesACS Nano201159977998322077198
- FriedrichIReichlSMüller-GoymannCCDrug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS)Int J Pharm200530516717516242276
- CollinsJACoshJATemperature and biochemical studies of joint inflammationAnn Rheum Dis1970293863894916768
- McAlindonTFormicaMSchmidCHFletcherJChanges in barometric pressure and ambient temperature influence osteoarthritis painAm J Med200712042943417466654
- RobinsonVBrosseauLCasimiroLThermotherapy for treating rheumatoid arthritisCochrane Database Syst Rev20022CD00282612076454
- Barzegar-JalaliMAdibkiaKValizadehHKinetic analysis of drug release from nanoparticlesJ Pharm Pharm Sci20081116717718471378